Mon - Fri 8:00 am - 6:00 pm
admin@hackettfirm.com
Call Us: (415) 410-9931
Mon - Fri 8:00 am - 6:00 pm
admin@hackettfirm.com
Call Us: (415) 410-9931
A landmark peer-reviewed study published in the British Medical Journal found that women who used Depo-Provera for three or more years faced a dramatically elevated risk of developing meningioma — a serious intracranial tumor. Pfizer failed to warn patients. If you were affected, you may have a substantial claim. Fill out the form for more information »
💊 Defendant: Pfizer Inc.
🧠 Condition: Intracranial Meningioma
📍 Federal & California Courts
In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation
N.D. Illinois — 2024
BMJ, March 2024
18,000+ patients — 5× risk
Active
Pfizer Inc.
Pharmacia & Upjohn Co.
Hackett Law Firm is actively representing women who developed meningioma — a potentially life-altering intracranial tumor — after using Depo-Provera (depot medroxyprogesterone acetate), a progestin-based injectable contraceptive manufactured and sold by Pfizer. A major peer-reviewed study published in the British Medical Journal in 2024 found that long-term Depo-Provera use was associated with a fivefold increase in meningioma risk compared to non-users — a risk Pfizer knew or should have known about, yet failed to disclose to patients or prescribers.
“A tumor that grows from the meninges — the protective membranes surrounding the brain and spinal cord. While often classified as ‘benign,’ meningiomas can cause severe neurological symptoms, require brain surgery or radiation, and recur — with long-term and potentially permanent consequences.”
Defendants named in active litigation:
💊 Pfizer Inc.
Depo-Provera has been prescribed to millions of American women as a long-acting injectable contraceptive since FDA approval in 1992. Administered every three months, it contains medroxyprogesterone acetate (MPA) — a synthetic progestin. For decades, progestin hormones have been linked in scientific literature to meningioma growth, as these tumors frequently express progesterone receptors. Pfizer’s own label updates and internal communications show awareness of this biological connection, yet no adequate meningioma warning was ever added to U.S. labeling.
In March 2024, the British Medical Journal published a large-scale case-control study of over 18,000 meningioma patients in France that found a nearly fivefold elevated meningioma risk among women who had used Depo-Provera for more than one year. The finding triggered immediate regulatory action in France and a cascade of U.S. litigation.
Women affected by Depo-Provera-linked meningioma may be diagnosed with either a primary concern tumor that requires immediate intervention, or a tumor that is currently monitored but remains a source of serious ongoing neurological and psychological harm. Either may form the basis of a valid legal claim.
Meningioma symptoms develop gradually as the tumor presses on brain tissue. Many women initially attribute symptoms to stress, aging, or hormonal changes — and are not diagnosed for months or years after the tumor begins growing. The following are the primary harms being pursued in active litigation:
If you used Depo-Provera injections — particularly for a year or more — and were subsequently diagnosed with a meningioma, you may have a viable failure-to-warn and products liability claim against Pfizer. You do not need to have undergone surgery to qualify; an asymptomatic meningioma requiring ongoing monitoring is itself a compensable harm.
California women have particularly strong grounds under state law, which provides additional product liability protections and allows claims based on the failure to warn of known risks even where the drug itself is otherwise effective. Our attorneys will review your prescription history, imaging records, and diagnosis at no cost to you.
Our legal team alleges that Pfizer and its predecessors knew for years that medroxyprogesterone acetate was biologically linked to meningioma growth — given the progesterone-receptor-expressing nature of these tumors — yet failed to update U.S. labeling to reflect this risk. French regulators, citing the 2024 BMJ study, required immediate label changes and restricted prescribing. Pfizer’s inaction in the United States during the same period forms a core element of our negligence and failure-to-warn claims.
Additional claims include breach of implied warranty, strict products liability, and violations of California’s consumer protection statutes. An MDL is actively underway, and new plaintiffs are still being signed by Hackett Law Firm.
Complaint 01/26/26
In no case will any plaintiff ever be asked to pay any out-of-pocket sum. Hackett Law Firm handles all Depo-Provera meningioma cases on a contingency fee basis — meaning we only get paid if and when we secure compensation for you. In the event a settlement or judgment is reached, the court will determine a reasonable legal fee from that recovery. You pay nothing upfront, ever.